Associations were observed between ZnT3 and PSD95 levels in prefrontal cortex and cognitive impairment (p=0.001 and p=0.002 respectively), and between ZnT3 levels in the parietal cortex and cognitive impairment (p=0.036). Associations were also seen between ZnT3 levels in cingulate cortex and severity of amyloid-β (p=0.003) and tau pathology (p=0.011). DLB and PDD were characterized by significant reductions of PSD95 (p<0.05) and ZnT3 (p<0.001) in prefrontal cortex compared to controls and AD. PSD95 levels in the parietal cortex were found to be decreased in AD cases compared to controls (p=0.02) and PDD (p=0.005).
This study has identified Zn2+ modulation as a possible novel target for the treatment of cognitive impairment in DLB and PDD, and the potential for synaptic proteins to be utilised as biomarkers for the differentiation of DLB and PDD from AD.
|Number of pages
|Neurobiology of Aging
|Published - Dec 2014